Form 4: Paul M. Silva, Director at Nurix Therapeutics, Acquires 25,000 Stock Options

Director Paul M. Silva acquired 25,000 stock options in Nurix Therapeutics on May 20, 2024, vesting fully by May 20, 2025, subject to continued service.

Summary

• Paul M. Silva, a director at Nurix Therapeutics, acquired 25,000 stock options on May 20, 2024.
• The exercise price of these options is $16.19.
• The options vest 100% on the earlier of the next annual meeting of the Issuer's stockholders or May 20, 2025, contingent upon Silva's continued service to the company.
• The expiration date for these options is May 19, 2034.
• Following this transaction, Silva directly owns 25,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine disclosure of stock option grants to a director, which is a common practice.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedule implies an expectation of continued service by the director.

Industry Context

This is a standard Form 4 filing, reflecting insider transactions. Option grants are a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially incentivizing value creation.

Key Dates